Advertisement

Current Atherosclerosis Reports

, Volume 14, Issue 1, pp 60–69 | Cite as

Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus

  • Leon I. Igel
  • Amanda G. Powell
  • Caroline M. Apovian
  • Louis J. AronneEmail author
Nonstatin Drugs (W Borden, Section Editor)

Abstract

Overweight and obesity are now recognized as leading causes of diseases such as type 2 diabetes, hypertension, hyperlipidemia, and ultimately, cardiovascular disease. Despite the serious consequences, roughly two thirds of Americans are presently classified as overweight, and about one third are classified as obese. Weight loss via lifestyle modification and pharmacotherapy can promote improvement in many of these obesity-related conditions. This review addresses recent advances in pharmacotherapy for the management of obesity and obesity-related co-morbidities, with a focus on the management of obesity specifically in individuals with type 2 diabetes. Emphasis is also placed on a proposed paradigm shift from the glucose-centric to the weight-centric management of type 2 diabetes mellitus.

Keywords

Weight loss Weight management Obesity Type 2 diabetes Pharmacotherapy Glycemic control Weight-centric management of type 2 diabetes 

Notes

Disclosure

L.I. Igel: none. A.G. Powell: none. C.M. Apovian is a paid advisory board member for Amylin, Merck, Johnson and Johnson, Abbott, Sanofi-Aventis, Allergan, Orexigen, and Arena; has provided expert testimony for Allergan and Orexigen; and has received grants from the Atkins Foundation, Amylin, and MetaProteomics. L.J. Aronne is a paid scientific advisory board member for and has had travel expenses reimbursed by Orexigen, Ethicon Endo-Surgery, Novo Nordisk, VIVUS, Amylin, Pfizer, Sanofi-Aventis, Merck, and Johnson and Johnson; is a consultant for NeuroSearch, Takeda, GlaxoSmithKline, Abbott, Wyeth, and Allergan; has provided expert testimony for VIVUS; has received grants from Orexigen, Novo Nordisk, Amylin, F. Hoffman-La Roche, Pfizer, Merck, Arena, VIVUS, Schering-Plough, TransTech Pharma, MetaCure, and Metabolous Pharmaceuticals; and owns stock/stock options in Atlas Therapeutics and Cardiometabolic Support Network.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    American Heart Association. Overweight and Obesity Statistics – 2009 Update. Available at: http://www.americanheart.org/downloadable/heart/1236358025411OVRWGHT.pdf
  2. 2.
    • Flegal KM, Carroll MD, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41. The authors examined trends in obesity from 1999 through 2008 and also assessed the prevalence of obesity and overweight for 2007–2008. The authors found a very high prevalence of obesity in the US (32.2% among adult men and 35.5% among adult women). PubMedCrossRefGoogle Scholar
  3. 3.
    FinkelsteinEA JGTrogdon, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Heal Aff. 2009;28(5):w822–31. Available at: http://content.healthaffairs.org/cgi/reprint/28/5/w822.CrossRefGoogle Scholar
  4. 4.
    United Health Foundation. America’s Health Rankings —20th Anniversary highlights (2010). Available at: http://www.americashealthrankings.org/2009/highlights.aspx
  5. 5.
    Aronne LJ. A practical guide to drug-induced weight gain. Minneapolis: McGraw-Hill; 2002. p. 77–91.Google Scholar
  6. 6.
    • Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59. The authors examined whether intensive glucose lowering therapy targeting normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. The authors found that intensive glucose lowering therapy actually increased mortality and did not significantly reduce major cardiovascular events in this high-risk population. PubMedCrossRefGoogle Scholar
  7. 7.
    Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9:326S–34S.PubMedCrossRefGoogle Scholar
  8. 8.
    NHLBI Obesity Education Initiative Working Group: The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. NIH/NHLBI/NAASO; October 2000. NIH Publication 00 -4084Google Scholar
  9. 9.
    Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152(6):346–57.PubMedGoogle Scholar
  10. 10.
    Koska J, Ortega E, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia, Springer Berlin/Heidelberg. 2009;52:385–93.Google Scholar
  11. 11.
    Over-the-counter weight loss with orlistat? Drug Ther Bull. 2009;47(11):125–127.Google Scholar
  12. 12.
    Torgerson JS, Hauptman J, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27(1):155–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Genentech USA, Inc. Xenical (Orlistat) Package Insert. Revised December 2010. http://www.gene.com/gene/products/information/xenical/pdf/pi.pdf
  14. 14.
    Hauptman J, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Rössner S, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8:49–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Bristol-Myers Squibb Company, Glucophage (metformin) package insert. Rev. January 2009 http://packageinserts.bms.com/pi/pi_glucophage.pdf
  17. 17.
    Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRefGoogle Scholar
  18. 18.
    DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. NEJM. 1995;333(9):541–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Robinson AC, Burke J, et al. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 1998;21(5):701–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1–14.PubMedCrossRefGoogle Scholar
  21. 21.
    • The Look AHEAD Research Group (2010). Long term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: four year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566–75. The authors examined the effects of intensive lifestyle intervention as compared to a control condition of diabetes support and education on changes in weight, fitness, and cardiovascular disease risk factors in 5145 overweight or obese subjects with type 2 diabetes over 4 years. They found that intensive lifestyle intervention produced sustainable weight loss as well as improvements in fitness, glycemic control, and cardiovascular disease risk factors. CrossRefGoogle Scholar
  22. 22.
    Amylin Pharmaceuticals and Eli Lilly & Company. Byetta Package Insert. Rev: September 2010 http://pi.lilly.com/us/byetta-pi.pdf
  23. 23.
    Moretto T, Milton D, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–60.PubMedCrossRefGoogle Scholar
  24. 24.
    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus. Diabetes Care. 2005;28:1092–100.PubMedCrossRefGoogle Scholar
  25. 25.
    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Blonde L, Klein EJ, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436–47.PubMedCrossRefGoogle Scholar
  28. 28.
    Buse JB, Klonoff DC, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo controlled trials. Clin Ther. 2007;29:139–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Horton ES, Silberman C, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33(8):1759–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Merck & Co., INC. Januvia (Sitagliptin) Package Insert. 9984404. Revised 2010. Available at: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf
  31. 31.
    Bray G. Gastrointestinal hormones and weight management. Lancet. 2009;374(9701):1570–1.PubMedCrossRefGoogle Scholar
  32. 32.
    Russell-Jones D, et al. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297(1–2):137–40.PubMedCrossRefGoogle Scholar
  33. 33.
    • Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81. The authors investigated the safety and efficacy of liraglutide as monotherapy as compared to glimepiride monotherapy in 746 subjects with type 2 diabetes over 52 weeks. They found that liraglutide was effective in the treatment of type 2 diabetes mellitus and led to greater reductions in HbA1c, weight, and blood pressure than did glimepiride without the risk of hypoglycemia. PubMedCrossRefGoogle Scholar
  34. 34.
    Nauck MA, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care. 2009;32:84–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. J Clin Endocrinol Metab. 2011;96:1301–10. Epub 2011 Feb 9. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.PubMedCrossRefGoogle Scholar
  36. 36.
    Amylin Pharmaceuticals. Symlin (pramlintide) Package Insert. 812003-CC Revised July 2008. Available at: https://www.symlin.com/pdf/SYMLIN-pi-combined.pdf
  37. 37.
    Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year randomized controlled trial. Diabet Med. 2004;11:1204–12.CrossRefGoogle Scholar
  38. 38.
    Younk LM, Mikeladze M, et al. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12(9):1439–51.PubMedCrossRefGoogle Scholar
  39. 39.
    Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;3:784–90.CrossRefGoogle Scholar
  40. 40.
    Aronne L, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92(8):2977–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Aronne LJ, Isoldi KK, Roarke DT. The Johns Hopkins University textbook of dyslipidemia chapter 24: therapeutic options for modifying obesity and cardiometabolic risk factors. Kwiterovich PO, editor. Lippincott, Williams and Wilkins; 2009. pp. 277–91.Google Scholar
  42. 42.
    Smith SR, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816–23.PubMedCrossRefGoogle Scholar
  43. 43.
    Ravussin E, Smith SR, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009;17(9):1736–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Amylin Pharmaceuticals press release July 9, 2009. Amylin Pharmaceuticals Announces Positive Results from dose ranging clinical study of Pramlintide/Metreleptin Combination Treatment for Obesity. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1305954
  45. 45.
    Amylin Pharmaceuticals press release October 1, 2008. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of the Obesity Society. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1204556&highlight
  46. 46.
    Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin N Am. 2005;39(1):69–79.CrossRefGoogle Scholar
  47. 47.
    Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26:262–73.PubMedCrossRefGoogle Scholar
  48. 48.
    Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–46.PubMedGoogle Scholar
  49. 49.
    Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology. 2007;132:2239–52.PubMedCrossRefGoogle Scholar
  50. 50.
    Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011 Apr 28. [Epub ahead of print].Google Scholar
  51. 51.
    • Gadde KM, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52. The authors assessed the efficacy and safety of phentermine plus topiramate controlled-release combination in 2487 individuals who were overweight and obese with two or more risk factors. They found that phentermine plus topiramate produced significant weight loss as well as improvement in many metabolic risk factors over the 56 weeks of the trial. PubMedCrossRefGoogle Scholar
  52. 52.
    • Greenway FL, Fujioka K, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605. The authors assessed the effect of sustained-release naltrexone and bupropion on bodyweight in 1742 overweight and obese subjects and found that the combination promoted significant weight loss as well as improvements in many metabolic risk factors. PubMedCrossRefGoogle Scholar
  53. 53.
    • Smith SR, Weissman NJ, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56. The authors evaluated the use lorcaserin as compared to placebo in 3182 overweight and obese adults over 52 weeks. They found that lorcaserin promoted significant weight loss as well as improvements in many metabolic risk factors. PubMedCrossRefGoogle Scholar
  54. 54.
    Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323–30.PubMedCrossRefGoogle Scholar
  55. 55.
    • Bailey CJ, Gross JL, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223–33. The authors evaluated the adjunct use of dapagliflozin in 546 individuals with type 2 diabetes treated with metformin over 24 weeks. They found that dapagliflozin promoted significant weight loss as well as improved glycemic and blood pressure control. PubMedCrossRefGoogle Scholar
  56. 56.
    Musso G, Gambino R, et al. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2011; Apr 15. [Epub ahead of print]1-19.Google Scholar
  57. 57.
    Siram AT, Yanagisawa R, Skamagas M. Weight management in type 2 diabetes mellitus. Mount Sinai J Med. 2010;77:533–48.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Leon I. Igel
    • 1
  • Amanda G. Powell
    • 2
  • Caroline M. Apovian
    • 3
  • Louis J. Aronne
    • 4
    Email author
  1. 1.Department of MedicineNew York Presbyterian/Weill Cornell Medical CenterNew YorkUSA
  2. 2.Division of Endocrinology, Diabetes and Nutrition, Department of MedicineBoston University School of MedicineBostonUSA
  3. 3.Division of Endocrinology, Diabetes and Nutrition, Department of MedicineBoston University School of MedicineBostonUSA
  4. 4.Department of MedicineWeill Cornell Medical College, Comprehensive Weight Control Program, New York-Presbyterian HospitalNew YorkUSA

Personalised recommendations